H. Tiddens (Rotterdam, The Netherlands), L. Dracea (Brasov, Romania)
Reduced exhaled nitric oxide in infants with cystic fibrosis
P. J. Franklin, G. Hall, F. Horak, A. Moeller, S. M. Stick (Perth, Australia)
|  |
Nasal NO measurements during tidal breathing and humming in healthy subjects and patients with CF
K. M. De Winter - de Groot, I. Prins, J. M. Tersmette, C. K. van der Ent (Utrecht, The Netherlands)
| |
Antibiotic treatment decreases exhaled nitric oxide levels in cystic fibrosis patients
B. Antus, E. Csiszer, I. Horvath (Budapest, Hungary)
| |
Correlation between decrease of leukotriene B-4 and reactive protein C in cystic fibrosis patients
E. Bucchioni, D. Costantini, F. Blasi, T. Cappelletti, A. Brivio, C. Colombo, L. Allegra (Milan, Italy)
| |
Inflammatory cytokines in airway secretions from patients with cystic fibrosis contribute to airway epithelial cell damage
S. Mitola, E. Ponte, V. Sorbello, M. Goia, M. Bardessono, F. Bussolino, V. De Rose (Turin, Candiolo, Italy)
| |
Neutrophil functional activity of patients with cystic fibrosis
T. Bulgakova, E. Surkova, T. Ses, G. Aleshina, E. Boitsova, T. Gembitskaya (St Petersburg, Russia)
| |
Dysregulation of systemic and local immune response in cystic fibrosis patients with chronic P. aeruginosa infection
A. L. Pukhalsky, G. V. Shmarina (Moscow, Russia)
| |
Antineutrophil cytoplasmic antibodies (ANCA) and antinuclear antibodies (ANA) in cystic fibrosis (CF)
M. M. Filewska, U. Demkow, W. Skorupa, J. Kus, E. Skopinska-Rozewska (Warsaw, Poland)
| |
The association between polymorphisms of GSTM1 genes and severity clinical picture in CF children
L. A. Zhelenina, N. S. Efimova, T. E. Ivaschenko (St Petersburg, Russia)
| |
Pseudomonas aeruginosa DNA-fingerprinting register in Belgian CF-patients: a one year survey
S. Van daele, M. Vaneechoutte, P. Schelstraete, G. Claeys, F. De Baets (Gent, Belgium)
| |
Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy
G. H. Thalhammer, B. Pratl, E. Eber, M. S. Zach (Graz, Austria)
| |
Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition?
J. Mainz, K. Dawczynski, A. Huebler, P. Nardella, D. van Devanter, F. Zintl (Jena, Germany; Seattle, United States Of America)
| |
Are patients with cystic fibrosis of six years and older able to use dry powder inhalers? A study of the effect of device resistance on flows and volumes
H. A. Tiddens, T. Standaert, P. Challoner, R. J. Spiers, K. C. Kesser, S. E. Overbeek, D. Humble, S. Shrewsbury, D. E. Geller (Rotterdam, The Netherlands; Seattle, Orlando, United States Of America)
| |
Thoracic excursions as an effect parameter for in hospital treatment of pulmonary exacerbations in cystic fibrosis patients
B. G. M. Arets, J. W. H. Custers (Utrecht, The Netherlands)
| |
Effect of supine posture on respiratory values in patients with cystic fibrosis
V. Fasano, E. Bucchioni, D. Costantini, C. Colombo, A. Brivio, L. Allegra (Milan, Italy)
| |
Role of the specific airway resistance (sRaw) in 4-6 years fibrosis cistic patients
E. Bucchioni, D. Costantini, A. Brivio, C. Colombo, L. Allegra (Milan, Italy)
| |
The assessment of respiratory status using impulsive oscillometry in children with cystic fibrosis
A. Minarowska, M. Kaczmarski, L. Minarowski, M. Mrugacz (Bialystok, Poland)
| |
Clearance from small airways independent of normal ciliary funtion
M. Lindström, R. Falk, L. Hjelte, K. Philipson, M. Svartengren (Stockholm, Sweden)
| |
Comparison of high resolution computerized tomography (HRCT) of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis (CF) patients
S. Z. Nasr, D. Gordon, E. Sakmar, B. P. Eckhardt, P. J. Strouse (Ann Arbor, Seattle, United States Of America)
| |